We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
-$143M
Cap. Flow
-$225M
Cap. Flow %
-13.99%
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$21.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.6M
3
OMDA
Omada Health Inc
OMDA
+$15.9M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.1M
5
ACLX
Arcellx
ACLX
+$11.6M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$85.4M
2
NUVL
Nuvalent
NUVL
+$24.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$21.8M
4
UNH icon
UnitedHealth
UNH
+$19.1M
5
LEGN icon
Legend Biotech
LEGN
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$16.7B
$11.2M 0.7%
88,800
-190,200
-68% -$21.8M
PHVS icon
52
Pharvaris
PHVS
$2.46B
$11M 0.68%
623,402
– –
EW icon
53
Edwards Lifesciences
EW
$53.4B
$10.2M 0.64%
131,000
-124,000
-49% -$9.25M
NAMS icon
54
NewAmsterdam Pharma
NAMS
$3.34B
$9.71M 0.61%
536,111
– –
ARDX icon
55
Ardelyx
ARDX
$984M
$8.96M 0.56%
2,286,273
+681,298
+42% +$2.81M
NUVL
56
DELISTED
Nuvalent
NUVL
$7.12M 0.44%
93,328
-334,204
-78% -$24.5M
ACRS icon
57
Aclaris Therapeutics
ACRS
$863M
$6.77M 0.42%
4,769,309
-277,000
-5% -$375K
CDTX
58
DELISTED
Cidara Therapeutics
CDTX
$6.53M 0.41%
+134,133
New +$3.22M
ZBIO
59
Zenas BioPharma
ZBIO
$2.03B
$6.21M 0.39%
640,467
-238,200
-27% -$2.32M
REGN icon
60
Regeneron Pharmaceuticals
REGN
$82.9B
$5.93M 0.37%
11,300
+8,500
+304% +$4.74M
COGT icon
61
Cogent Biosciences
COGT
$7.04B
$5.75M 0.36%
+800,199
New +$4.44M
DYN icon
62
Dyne Therapeutics
DYN
$4.91B
$5.53M 0.34%
580,998
+56,499
+11% +$622K
CGEM icon
63
Cullinan Oncology
CGEM
$1.16B
$5.03M 0.31%
668,233
+23,600
+4% +$190K
JANX icon
64
Janux Therapeutics
JANX
$996M
$4.86M 0.3%
210,266
+5,800
+3% +$153K
MLYS icon
65
Mineralys Therapeutics
MLYS
$2.39B
$4.39M 0.27%
324,513
+3,700
+1% +$53.6K
TMO icon
66
Thermo Fisher Scientific
TMO
$220B
$4.05M 0.25%
+10,000
New +$4.18M
GOSS icon
67
Gossamer Bio
GOSS
$87.4M
$4.02M 0.25%
3,266,960
– –
IMVT icon
68
Immunovant
IMVT
$8.13B
$3.54M 0.22%
221,500
-754,303
-77% -$11.4M
AMLX icon
69
Amylyx Pharmaceuticals
AMLX
$2.5B
$3.2M 0.2%
499,764
+156,536
+46% +$761K
BCAX
70
Bicara Therapeutics
BCAX
$1.82B
$3.12M 0.19%
336,070
– –
JSPR icon
71
Jasper Therapeutics
JSPR
$26.4M
$3.03M 0.19%
545,171
– –
PRTA icon
72
Prothena Corp
PRTA
$452M
$2.99M 0.19%
492,601
– –
ATEC icon
73
Alphatec Holdings
ATEC
$1.44B
$2.97M 0.19%
267,500
– –
LENZ
74
LENZ Therapeutics
LENZ
$167M
$2.46M 0.15%
83,982
+900
+1% +$24.5K
FOCL
75
EDAP TMS S.A.
FOCL
$234M
$2.1M 0.13%
1,270,000
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rock Springs Capital Management held 105 positions worth $1.6B, down 8.2% from $1.75B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $225M in Q2 2025, closing 12 positions and reducing 29 holdings. Its most notable exit was Legend Biotech, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Caris Life Sciences worth $21.2M.

  • Rock Springs Capital Management's largest Q2 2025 buy was Caris Life Sciences: 793,651 shares worth $21.2M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q2 2025, an estimated $19.6M increase.
  • Rock Springs Capital Management's biggest Q2 2025 reduction was Blueprint Medicines, cutting an estimated $85.4M.
  • Rock Springs Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $17.4M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $1.6B portfolio in Q2 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 12 in Q2 2025.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.